Collection
Advances in Nanoparticle-Mediated Drug Delivery for Cancer Therapeutics
Development in fundamental knowledge and engineering sciences helps the field of pharmaceutics. Nanotechnology-based materials are emerging as drug delivery carriers, especially in cancer therapeutics. The Topical Collection entitled Advances in Nanoparticle-Mediated Drug Delivery for Cancer Therapeutics calls for cutting-edge research and review manuscripts dealing with insights of current developments of nanoparticles for targeted drug delivery in the treatment of cancer. The collection will be focused on molecular drug targets, including cancer-specific proteins, enzymes, and genes, which seek to elucidate the impact of new therapeutic agents on patient acceptability, preference, satisfaction and improvement in the quality of life of cancer patients.
Editors
-
Stefano Leporatti
Stefano Leporatti, Research Director, CNR Insitute of Nanotechnology, Italy. From 2001-2006 SL has been Research Scientist at the Universität Leipzig, Leipzig (Germany). From 2006 to 2008 he was a Senior Researcher and NanoCarriers and BioMechanics Group Leader at the National Nanotechnology Laboratory (NNL) of CNR-INFM in Lecce, Italy. In 2015 SL joined the CNR Insitute of Nanotechnology in Lecce as CNR Senior Researcher ( by the end of 2018 as a permanent Researcher). Since October 2020 SL is CNR Research Director at the CNR Insitute of Nanotechnology in Lecce.
-
Raghvendra A Bohara
Raghvendra A Bohara, Researcher, University of Galway, Ireland. He has a broad interdisciplinary background in science, beginning with a degree in Pharmacy, Honorary Graduation in Zoology, a Postgraduate in Biochemistry, and a PhD in Material Science and Nanomedicine. His research work is revolving around Targeted Drug Delivery, Extracellular based materials, Glycobiology, Nanoparticles, Magnetic materials, Cancer Nanomedicine, and Bioadhesive. He has published more than 60 plus manuscripts in leading international journals.
Articles (12 in this collection)
-
-
Advances, limitations and perspectives in the use of celecoxib-loaded nanocarriers in therapeutics of cancer
Authors (first, second and last of 6)
-
The use of nanomaterials as drug delivery systems and anticancer agents in the treatment of triple-negative breast cancer: an updated review (year 2005 to date)
Authors (first, second and last of 10)
-
From nature to nanomedicine: bioengineered metallic nanoparticles bridge the gap for medical applications
Authors (first, second and last of 6)
-
A comparative study on biosynthesized silver nanoparticles from H. undatus fruit peel and their therapeutic applications
Authors (first, second and last of 5)
-
-
Anti-CD38 targeted nanotrojan horses stimulated by acoustic waves as therapeutic nanotools selectively against Burkitt’s lymphoma cells
Authors (first, second and last of 8)
-
Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical review
Authors (first, second and last of 5)
-
An updated landscape on nanotechnology-based drug delivery, immunotherapy, vaccinations, imaging, and biomarker detections for cancers: recent trends and future directions with clinical success
Authors (first, second and last of 5)
-
A review on selenium and gold nanoparticles combined photodynamic and photothermal prostate cancer tumors ablation
Authors (first, second and last of 12)
-
Multimodal imaging and photothermal/chemodynamic therapy of cervical cancer using GSH-responsive MoS2@MnO2 theranostic nanoparticles
Authors (first, second and last of 14)
-
Preparation and anti-triple-negative breast cancer cell effect of a nanoparticle for the codelivery of paclitaxel and gemcitabine
Authors (first, second and last of 11)
